Article Text

Download PDFPDF
Management and in-hospital outcome of patients with acute myocardial infarction admitted to intensive care units at the turn of the century: results from the French nationwide USIC 2000 registry
  1. G Hanania1,
  2. J-P Cambou5,
  3. P Guéret2,
  4. L Vaur6,
  5. D Blanchard3,
  6. J-M Lablanche4,
  7. Y Boutalbi6,
  8. R Humbert7,
  9. P Clerson7,
  10. N Genès6,
  11. N Danchin3,
  12. for the USIC 2000 Investigators
  1. 1CH Aulnay, France
  2. 2CHU Henri Mondor, Crétell, France
  3. 3Service de Cardiologie, HEGP, Paris, France
  4. 4Hôpital Cardiologique, CHRU de Lille, France
  5. 5INSERM U 558, Toulouse, France
  6. 6Laboratoire Aventis, Paris, France
  7. 7Orgamétrie, Wasquehal, France
  1. Correspondence to:
    Dr Nicolas Danchin
    Service de Cardiologie, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France;


Objective: To assess actual practices and in-hospital outcome of patients with acute myocardial infarction on a nationwide scale.

Methods: Of 443 intensive care units in France, 369 (83%) prospectively collected data on all cases of infarction (within < 48 hours of symptom onset) in November 2000.

Results: 2320 patients (median age 68 years, 73% men) were included, of whom 83% had ST segment elevation infarction (STEMI). Patients without STEMI were older and had a more frequent history of cardiovascular disease. Median time to admission was 5.0 hours for patients with and 6.5 hours for those without STEMI. Reperfusion therapy was used for 53% of patients with STEMI (thrombolysis 28%, primary angioplasty 25%). In-hospital mortality was 8.7% (5.5% of patients without and 9.3% of those with STEMI). Multivariate analysis found that age, Killip class, lower blood pressure, higher heart rate on admission, anterior location of infarct, STEMI, diabetes mellitus, previous stroke, and no current smoking independently predicted in-hospital mortality. At hospital discharge, 95% received antiplatelet agents, 75% received β blockers, and over 60% received statins. Angiotensin converting enzyme inhibitors were prescribed for 40% of the patients without and 52% of those with ST elevation.

Conclusions: This nationwide registry, including all types of centres irrespective of their size and experience, shows continued improvement in patient care and outcomes. Time from symptom onset to admission, however, has not improved in recent years and reperfusion therapy is used for just over 50% of patients with STEMI, with an increasing use of primary angioplasty.

  • 4S, Scandinavian simvastatin survival study
  • ACE, angiotensin converting enzyme
  • CARE, cholesterol and recurrent events
  • CONSENSUS, cooperative new Scandinavian enalapril survival study
  • ESSENCE, efficacy and safety of subcutaneous enoxaparin in unstable angina and non-Q wave myocardial infarction
  • GISSI, Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico
  • ISIS-4, fourth international study of infarct survival
  • LIPID, long-term intervention with pravastatin in ischaemic disease
  • LVEF, left ventricular ejection fraction
  • MITI, myocardial infarction triage and intervention
  • MONICA, monitoring trends and determinants in cardiovascular disease
  • NSTEMI, non-ST segment elevation myocardial infarction
  • PCI, percutaneous coronary intervention
  • STEMI, ST segment elevation myocardial infarction
  • TIMI, thrombolysis in myocardial infarction
  • myocardial infarction
  • intensive care units
  • in-hospital outcome

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.